Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tech Transfer Roundup: United Neuroscience Unveils Pair Of Collaborations In CTE, Alzheimer’s

Executive Summary

Irish biotech focused on Endobody vaccine candidates partners with Boston U. in CTE and U. of Texas in Alzheimer’s. Lupus Research Alliance affiliate will help Bristol conduct a Phase II trial of Tyk2 inhibitor in lupus.

You may also be interested in...



United Neuroscience Hopes To Revive Vaccine Approach To Alzheimer’s

Emerging Company Profile: Dublin-based United Neuroscience, spun out of an animal vaccine maker, believes it can pick up and improve upon a vaccine approach to Alzheimer’s that was abandoned nearly two decades ago due to safety issues.

Next-Generation CAR-Ts Tackle First-Generation Safety, Solid Tumor Challenges

New strategies to overcome safety, solid tumor and other challenges associated with CAR-T therapies – and some early clinical data for patients treated with Poseida's, Celyad's and Autolus' novel products – were featured at the American Association for Cancer Research (AACR) meeting.

Network-Driven Discovery – The Solution To Pharma's Productivity Challenge?

Ray Barlow, CEO of e-Therapeutics, talks to Scrip on the sidelines of the BIO-Europe partnering conference in Berlin, Germany, about network-driven discovery and its use by today's innovative pharma sector.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC123044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel